PRESS RELEASE

Development of ALS therapy by restoring the immune balance

License and collaboration agreement signed between Treeway and Amarna Therapeutics

Rotterdam, June 23rd 2014 - Treeway and Amarna Therapeutics join forces and form a collaboration to identify new therapeutic targets for the treatment of ALS. The aim of the project is to screen for new targets which play a role in both the cause and progression of ALS using the patented viral gene delivery platform SVac. With this collaboration, Treeway and Amarna Therapeutics hope this may ultimately lead to a new therapy for patients with Lou Gehrig’s Disease or Amyotrophic Lateral Sclerosis (ALS).

The objective of this collaboration is to investigate the role of the adaptive immune system in ALS, with the final aim to develop a reverse vaccine to stop disease progression. This research will lead to new insights in both the cause and progression of ALS. Inez de Greef, CEO of Treeway; "This study clearly underpins the ambition of our founders and could ultimately bring both a therapy as well as a diagnostic screening tool based on the changes in the adaptive immune system which occur in ALS."

Ben van Leent, CEO of Amarna adds: "After developing our SVac gene delivery platform, we are excited to enter the area of high unmet diseases, like ALS. We are convinced that the combination of the expertise of Treeway, Amarna Therapeutics and our research partner CABIMER in Seville will lead to the development of breakthrough solutions for ALS."

Note for the editor

ALS
Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s Disease, is a relentless progressive neurodegenerative disease that causes muscle weakness, disability and eventually death, with a median survival of three years. To date, there is no cure for ALS.

Treeway
Treeway has been founded by entrepreneurs Bernard Muller and Robbert Jan Stuit, both diagnosed with ALS. Treeway’s strategy is founded on a cohesive combination of approaches, that together should provide the highest likelihood of bringing successful treatments for ALS to the patient in the short term.

For further questions about Treeway, please contact Treeway at info@treeway.nl or +31 10 298 88 88.

Amarna Therapeutics
Amarna Therapeutics, a privately held Biotech company founded in 2008 with its head office in Leiden, The Netherlands, and its research facility in Seville, Spain, has developed the SVac viral gene delivery vector platform, the key to the success of gene therapy and therapeutic vaccines. SVac is safe, highly efficient and non-immunogenic in humans, creating opportunities to treat diseases with high unmet clinical need including genetic disorders, autoimmune diseases, infectious diseases and cancer. For further questions about Amarna Therapeutics, please contact Amarna Therapeutics at info@amarnatherapeutics.com or +31 71 332 21 92.

END OF RELEASE